BioPharmSignal logoBioPharmSignal

Biotech News

Veru to Present at The Society on Sarcopenia, Cachexia, and Wasting Disorders 18th International Conference and Regulatory and Clinical Trials Update Regulatory Workshop

Veru Inc (VERU)Veru IncConference / presentation

VERU (VERU) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is veru.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

VERUVeru Inc2026-07-07 12:30 EST

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

RVMDRevolution Medicines2026-06-24 23:31 EST

Revolution Medicines to Present Clinical Data from RAS(ON) Inhibitor Combination Trials in Pancreatic Cancer at ESMO Gastrointestinal Cancers Congress 2026

REPLReplimune Group2026-05-31 12:00 EST

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

ZNTLZentalis2026-07-17 20:15 EST

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026

TEVATeva Pharmaceutical Industries2026-06-01 20:30 EST

Teva to Present at the Goldman Sachs Global Healthcare Conference

LUNGPulmonx2026-07-28 20:05 EST

Pulmonx to Present at the Canaccord Genuity 46th Annual Growth Conference

KURAKura Oncology2026-07-14 11:02 EST

Kura Oncology to Present First Long-Term Follow-Up Data Further Supporting Darlifarnib’s Potential to Enhance VEGFR-Targeted Therapy in Renal Cell Carcinoma at KCRS 2026

CMPXCompass Therapeutics2026-07-17 14:42 EST

Compass Therapeutics Announces Tovecimig Data Accepted for an Oral Presentation at the ESMO Congress 2026

BMEABiomea Fusion2026-06-03 12:00 EST

Biomea Fusion Announces Research Collaboration with University of Leicester to Evaluate Icovamenib in Combination with Semaglutide in Obesity

View all latest news

Veru Inc

Cardiometabolic and Inflammation Company Veru develops late-stage small molecules for cardiometabolic and inflammatory diseases. Enobosarm Enobosarm is an oral selective androgen receptor modulator being evaluated to preserve lean mass, physical function, and bone health during GLP-1-driven weight loss in older adults with...

Recent company news

VERUVeru Inc2026-08-04 12:30 EST

Veru Announces Notice of Allowance for Key Methods of Use U.S. Patent for Enobosarm in Combination with Semaglutide for Quality Weight Loss

VERUVeru Inc2026-08-03 12:30 EST

Veru to Report Fiscal 2026 Third Quarter Financial Results on August 10th

VERUVeru Inc2026-07-30 12:30 EST

Veru to Participate in Fireside Chat at the Canaccord Genuity's 46th Annual Growth Investors Conference

VERUVeru Inc2026-07-27 12:10 EST

Veru Announces Full Enrollment for Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss

VERUVeru Inc2026-07-07 12:30 EST

Veru to Present at 2026 Obesity & Weight Loss Drug Development Summit and Pre-Conference Workshop Day

Stock data

Close
2.31 USD
Market cap
37.72M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States